Vertex Pharmaceuticals Q3 Adj EPS $4.08 Beats $3.98 Estimate, Sales $2.48B Miss $2.50B Estimate
Portfolio Pulse from bharat@benzinga.com
Vertex Pharmaceuticals reported Q3 earnings of $4.08 per share, beating the analyst consensus estimate of $3.98 by 2.51%. This is a 1.75% increase from the same period last year. However, the company's quarterly sales of $2.48 billion missed the analyst consensus estimate of $2.50 billion by 0.64%, though it's a 6.43% increase from last year.
November 06, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
VRTX beat Q3 earnings estimates but missed on sales. Earnings per share were $4.08, up 1.75% YoY, while sales were $2.48B, missing estimates by 0.64% but up 6.43% YoY.
VRTX's Q3 earnings beat estimates, which is positive for the stock. However, the company missed on sales, which could negatively impact the stock. The net effect could be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100